快速心房颤动伴胸痛患者肌钙蛋白与结局的关联:单中心10年队列回顾性研究
该单中心回顾性研究纳入2008-2017年急诊就诊的574例快速心房颤动伴疑似冠脉源性胸痛且至少检测一次肌钙蛋白的患者,按肌钙蛋白正常/升高分组,随访至2019年12月。中位随访3.8年,34.8%发生主要不良心血管事件(MACE)。肌钙蛋白升高独立关联MACE(校正HR 1.502,95%CI 1.130-1.998)、ACS(校正HR 2.488)、I型心梗(校正HR 2.771)和卒中(校正HR 3.580),但与死亡、心血管死亡或血运重建无关。肌钙蛋白作为连续变量时,其浓度升高与MACE风险呈线性增加相关。
要点
- 快速房颤伴疑似冠脉源性胸痛患者中,34.1%肌钙蛋白升高,肌钙蛋白升高者MACE风险独立升高(校正HR 1.502,95%CI 1.130-1.998)。
- 肌钙蛋白升高与ACS(校正HR 2.488,95%CI 1.256-4.928)、I型心梗(校正HR 2.771,95%CI 1.212-6.333)、卒中(校正HR 3.580,95%CI 1.888-6.787)独立相关。
- 肌钙蛋白升高与死亡、心血管死亡或血运重建无独立关联。
- 肌钙蛋白作为连续变量时,浓度升高与MACE风险呈线性增加相关;性别间无交互作用。
适用人群与场景
- 2008-2017年单中心急诊就诊的连续患者,表现为疑似冠脉源性胸痛,伴有快速心房颤动,且至少检测一次肌钙蛋白。
- 中位年龄76.5岁(IQR 14),女性占56.8%。
诊断标准与关键阈值
- 肌钙蛋白升高:按原文分类为正常/升高,未给出具体界值。
研究设计与关键结果
- 研究类型:单中心回顾性队列研究,纳入574例患者,随访至2019年12月,中位随访3.8年(IQR 4.8)。
- 主要终点MACE(包括ACS、血运重建、卒中或全因死亡)发生于200例(34.8%)。
- 肌钙蛋白升高独立关联MACE:校正HR 1.502(95%CI 1.130-1.998)。
- 肌钙蛋白升高独立关联ACS:校正HR 2.488(95%CI 1.256-4.928)。
- 肌钙蛋白升高独立关联I型心肌梗死:校正HR 2.771(95%CI 1.212-6.333)。
- 肌钙蛋白升高独立关联卒中:校正HR 3.580(95%CI 1.888-6.787)。
- 肌钙蛋白升高与死亡、心血管死亡或血运重建无独立关联。
- 敏感性分析结果与主要结果一致;性别间无交互作用;肌钙蛋白作为连续变量时,浓度升高与MACE风险呈线性增加相关。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在快速心房颤动伴疑似冠脉源性胸痛的患者中,肌钙蛋白升高提示MACE、ACS、I型心梗和卒中风险升高,作者认为肌钙蛋白升高与不良心血管结局相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: The prognosis of myocardial infarction in patients with rapid atrial fibrillation (RAF) is poorly known. We sought to ascertain if troponin concentrations are associated with a higher risk of major adverse cardiovascular events (MACE) in patients with RAF and chest discomfort suggestive of coronary origin.
METHODS: We retrospectively reviewed all consecutive patients attending an emergency department of a single-center (2008-2017) with chest pain suggestive of coronary origin who had RAF and at least one troponin determination. Patients were classified as having normal/increased troponin. They were followed until December 2019 to detect MACE (primary outcome), which included acute coronary syndrome (ACS), revascularization, stroke, or all-cause death. In addition to cardiovascular death and type I myocardial infarction, these were considered secondary outcomes. The adjusted risk was determined by Cox regression, and sensitivity analysis were run. Relationship between troponin as a continuous variable and outcomes was also evaluated, as well as interaction by sex.
RESULTS: We included 574 patients (median = 76.5 years, IQR = 14, women 56.8%, increased troponin 34.1%) followed by a median of 3.8 years (IQR = 4.8). MACE occurred in 200 patients (34.8%). Increased troponin was independently associated with MACE (adjusted hazard ratio, 1.502, 95% CI, 1.130-1.998), ACS (adjusted hazard ratio, 2.488, 95% CI, 1.256-4.928), type I myocardial infarction (adjusted hazard ratio, 2.771, 95% CI, 1.212-6.333) and stroke (adjusted hazard ratio, 3.580, 95% CI, 1.888-6.787) but not with death, cardiovascular death or revascularization. Sensitivity analyses were consistent with these results. There was no interaction by sex. When assessed continuously, an increase in troponin concentrations was lineally associated with a steady increase in the risk of MACE.
CONCLUSIONS: In patients with RAF who complain of chest pain, increased troponin levels are related to adverse cardiovascular outcomes.
参考来源
- García A, Miota N, Miró Ò, et al. Association between troponin and outcome in patients with chest pain and rapid atrial fibrillation: a retrospective study of a single-center 10-year cohort. Eur J Emerg Med. 2022. PMID: 35579514. doi:10.1097/MEJ.0000000000000945
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。